There are 2949 resources available
6MO - Radiochemotherapy-induced changes in brain extracellular matrix are associated with tumour development in mouse recurrent glioblastoma model
Presenter: Alexandra Tsidulko
Session: Mini Oral - Basic Science
Resources:
Abstract
Slides
Webcast
1980MO - SENP1 knockdown suppresses tumour progression in lung adenocarcinoma by regulating AAT genes expression
Presenter: HONG CHENG
Session: Mini Oral - Basic Science
Resources:
Abstract
Slides
Webcast
9MO - C-Myc regulates the cancer stem-cell phenotype differentially induced by the individual silencing of AKT isoforms in pancreatic adenocarcinoma
Presenter: Hugo Arasanz
Session: Mini Oral - Basic Science
Resources:
Abstract
Slides
Webcast
LBA13 - Tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trial
Presenter: Giampaolo Bianchini
Session: Mini Oral - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
162MO - Neoadjuvant chemotherapy and immunotherapy in Luminal B BC: Results of the phase II GIADA trial
Presenter: Maria Vittoria Dieci
Session: Mini Oral - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
163MO - Randomized phase II study of eribulin-based neoadjuvant chemotherapy for triple-negative primary breast cancer patients stratified by homologous recombination deficiency status (JBCRG-22)
Presenter: Hiroko Bando
Session: Mini Oral - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
164MO - Impaired Ki67 response towards neoadjuvant endocrine therapy in luminal breast cancer is associated with mutations conferring endocrine resistance: WSG-ADAPT HR+/HER2- translational results
Presenter: Isabel Grote
Session: Mini Oral - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
LBA14 - De-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs trastuzumab+ET in early HR+/HER2+ breast cancer (BC): ADAPT-TP survival results
Presenter: Nadia Harbeck
Session: Mini Oral - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
165MO - Patient (pt) preference for the pertuzumab-trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) in HER2-positive early breast cancer (EBC): Primary analysis of the open-label, randomised crossover PHranceSCa study
Presenter: Joyce O'Shaughnessy
Session: Mini Oral - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
166MO - A phase III trial to compare the efficacy, safety, pharmacokinetics and immunogenicity of HD201 to trastuzumab in HER2+ early breast cancer patients (TROIKA)
Presenter: Pivot Xavier
Session: Mini Oral - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast